Medisys rejigs senior team ahead of change in focus
This article was originally published in Clinica
Executive Summary
UK syringe and glucose monitoring unit producer Medisys has elevated chief operating officer David Conn to the position of CEO, ahead of the company's planned transition from a product development business to a diversified medical devices company. His appointment, and two associated changes to the composition of the senior management, are designed to help the company maximise the commercial potential of products that are on the point of launch in the US.